Biotech News

Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting

Pacira BioSciences (PCRX)Pacira BioSciences2026-06-04 20:20 ESTCompany update

Election of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward Momentum Leading Independent Experts ISS, Glass Lewis and Egan-Jones Agree that DOMA Representation Is Not Warranted BRISBANE, Calif., June 4, 2026 /PRNewswire/ -- Pacira BioSciences, Inc.

Pacira BioSciences

Non-Opioid Pain Management Pacira BioSciences develops and commercializes non-opioid therapies for postsurgical and musculoskeletal pain. Its portfolio combines extended-release pharmaceuticals, a cryoanalgesia device and a locally administered gene-therapy program. EXPAREL EXPAREL is a multivesicular-liposome formulation of bupivacaine...

Recent company news

PCRXPacira BioSciences2026-08-07 12:00 EST

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PCRXPacira BioSciences2026-08-06 12:00 EST

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

PCRXPacira BioSciences2026-08-04 20:01 EST

Pacira BioSciences Reports Second Quarter 2026 Financial Results

PCRXPacira BioSciences2026-07-28 12:00 EST

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

PCRXPacira BioSciences2026-07-27 12:00 EST

Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

Stock data

Close: 25.58 USD
Market cap: 875.49M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States